壹、beta-硝基苯乙烯的應用—4-芳基四氫異喹啉、3-芳基吲哚、2-芐基苯並呋喃及2-芳基色滿衍生物的合成 貳、茚並異喹啉的合成

I. Application of beta-Nitrostyrene — Synthesis of 4-ArylTHIQ, 3-Arylindole, 2-Benzylbenzofuran, and 2-Arylnitrochroman Derivatives II. Synthesis of Indenoisoquinolines

黃傢裕(Huang Chia-Yu)

指導教授 ： 姚清發

國立臺灣師範大學/理學院/化學系/博士(2017年)

https://doi.org/10.6345/NTNU202202679

摘要

['本論文分為兩個章節，每章節各自獨立，包含前言、研究目標、實驗結果
與討論，以及結論。
第壹章節探討beta-硝基苯乙烯衍生物在化學合成上的發展性與應用性，可以分為四個部分，分別為4-芳基四氫異喹啉、3-芳基吲哚、2-芐基苯並呋喃及2-芳基色滿四種化合物的合成。第一部分，beta-硝基苯乙烯與芳環用三氯化鋁催化傅-克烷化反應合成硝基烷，其還原後的胺類以傅-克反應或皮克特-施彭格勒反應得到4-芳基四氫異喹啉衍生物；若將胺類以銅試劑催化烏爾曼反應則是新穎的3-芳基吲哚合成法，為第二部分。第三部分，將beta-硝基苯乙烯衍生物還原為硝基烷，經過內夫反應合環得到2-苄基苯並呋喃；第四部份則將硝基烯衍生物作為中間產物，在鹼催化下一鍋化合成2-芳基色滿。
第貳章節為茚並異喹啉的合成，分成三個部分，第一部分以2-碘苯甲醯胺與茚滿二酮為起始物，在乙腈中銅催環化反應得到茚並異喹啉衍生物。第二部分為第一部分的反應條件的改良，除了將溶劑改為水，也縮短了反應時間跟減少銅試劑的使用量。第三部分為茚並異喹啉的合成展望，嘗試由2-鹵苯甲酸與茚滿二酮作為起始物，在反應過程中加入胺類以一鍋化合成茚並異喹啉衍生物，可減少合成步驟並提升原子效益。']

關鍵字

4-芳基四氫異喹啉 ； 3-芳基吲哚 ； 2-苄基苯並呋喃 ； 2-芳基色滿 ； 茚並異喹啉

並列摘要

['The content of the thesis is divided into two chapters, each chapter individually including preface, research goal, results and discussions, and conclusion.
Chapter I discuss about the applicability of beta-nitrostyrene derivatives for the synthesis of four types of structurally different compounds such as 4-aryltetrahydroisoquinoline, 3-arylindole, 2-benzylbenzofuran and 2-arylchroman derivatives. This chapter is divided into four parts. In the first part, the amines derived from nitroalkanes, which was synthesized via AlCl3-catalyzed Friedel-Crafts alkylation and reductive amination of beta-nitrostyrenes and arenes, underwent Friedel-Crafts cyclization or Pictet-Spengler reaction to produce 4-aryltetrahydroisoquinolines. In the second part, the amines were treated with copper catalyst to furnish 3-arylindoles. For third and fourth parts, nitroalkene derivatives modified from beta-nitrostyrenes were subjected to Nef reaction to yield 2-benzylbenzofurans, or treated with base to do Michael addition to obtain 2-arylchroman derivatives.
Chapter II is the synthesis of indenoisoquinolines, and is divided into three parts. The first part using 2-iodobenzamides and 1,3-indandiones as starting materials, which were transformed into indenoisoquinoline derivatives by copper-catalyzed cyclization in acetonitrile . The second part deals with the water-mediated synthesis of the same compounds under reduced amount of copper catalyst. The third part is a progressive project. We replaced 2-iodobenzamides with 2-halobenzoic acids as starting materials, after coupling with 1,3-indandione the amine derivative could be inserted and cyclized to afford the desired indenoisoquinolines. This one-pot water-mediated synthesis can save synthetic steps and improve atom efficiency.']

並列關鍵字

3-aryltetrahydroisoquinoline ； 3-arylindole ； 2-benzylbenzofuran ； 2-arylchroman ； indenoisoquinoline

參考文獻

Part 1.

1. (a) M. J. Zanwar, V. Kavala, S. D. Gawande, C.-W. Kuo, T.-S. Kuo, M.-L. Chen, C.-H. He, C.-F. Yao, Eur. J. Org. Chem. 2013, 36, 8288-8298. (b) Z. Tu, B. R. Raju, T.-R. Liou, V. Kavala, C.-W. Kuo, Y. Jang, Y.-H. Shih, C.-C. Wang, C.-F. Yao, Tetrahedron 2009, 65, 2436-2442. (c) K.-H. Shen, J.-T. Liu, Y.-R. Wu, C.-F. Yao, Synth. Commun. 2007, 37, 3677-3687. (d) C. Lin, J. Hsu, M. N. V. Sastry, H. Fang, Z. Tu, J.-T. Liu, C.-F. Yao, Tetrahedron 2005, 61, 11751-11757. (e) M.-C. Yan, Y.-J. Jang, W.-Y. Kuo, Z. Tu, K.-H. Shen, T.-S. Cu, C.-H. Ueng, C.-F. Yao, Heterocycles 2002, 57, 1033-1048. (f) J.-T. Liu, Y.-J. Jang, Y.-K. Shih, S.-R. Hu, C.-M. Chu, C.-F. Yao, J. Org. Chem. 2001, 66, 6021-6028.

2. (a) Bondinell, W. E.; Chapin, F. W.; Girard, G. R.; Kaiser, C.; Krog, A. J.; Pavloff, A. M.; Schwartz, M. S.; Silvestri, J. S.; Vaidya, P. D.; Lam, B. L.; Wellman, G. R.; Pendleton, R. G. J. Med. Chem. 1980, 23, 506-511. (b) Stambach, J. F.; Kanmacher, I.; Jung, L.; Schott, C.; Heitz, C.; Stoclet, J. C. Eur. J. Med. Chem. 1993, 28, 427-432. (c) McNaugh, K. St. P.; Thull, U.; Carrupt, P.-A.; Altomare, C.; Cellamare, S.; Carotti, A.; Testa, B.; Jenner, P.; Marsden, C. D. Biochem. Pharmacol. 1996, 51, 1503-1511. (d) Clark et al. Patent: US20070015737 A1 2007. (e) Nakamura, S.; Nakashima, S.; Tanabe, G.; Oda, Y.; Yokota, N.; Fujimoto, K.; Matsumoto, T.; Sakuma, R.; Ohta, T.; Ogawa, K.; Nishida, S.; Miki, H.; Matsuda. H.; Muraoka, O.; Yoshikawa, M. Bioorg. Med. Chem.2013, 21, 779-787.

3. Xintria Pharmaceutical Cooperation, Inc. Patent: WO2010104595 A1 2010.

4. (a) Young, Y. C.; Kwon, O. S.; Han, E. S.; Song, J. H.; Shin, Y. K.; Lee, C. S. Biochem. Pharmacol.2002, 63, 495-505. (b) Yang, J.-H.; Li, L.; Wang, Y.-S.; Zhao, J.-F.; Zhang, H.-B.; Luo, S.-D. Helv. Chim. Acta 2005, 88, 2523-2526. (c) O’Brien, P.; Carrasco-Pozo, C.; Speisky, H. Chem. Biol. Interact. 2006, 159, 1-17. (d) Zhang, A.; Zhang, Y.; Branfman, A. R.; Baldessarini, R. J.; Neumeyer, J. L. J. Med. Chem. 2007, 50, 171-181. (e) Han, Z.; Zheng, Y.; Chen, N.; Luan, L.; Zhou, C.; Gan, L.; Wu, Y. J. Chromatogr. A 2008, 1212, 76-81.